Please login to the form below

Not currently logged in

Boehringer/ Elan antibody deal

Boehringer Ingelheim has announced a partnership with Elan to develop and manufacture antibody-based therapeutics

Boehringer Ingelheim has announced a partnership with Ireland-based Elan to develop and manufacture antibody-based therapeutics.

German drugmaker, Boehringer said the global deal will see Elan lead the discovery and clinical development of antibodies, with Boehringer to take over the clinical manufacturing and regulatory filing.

"The agreement enables Elan to focus resources on discovery and the clinical progression of our science while leveraging Boehringer Ingelheim's process development and production capabilities," said Dr Johannes Roebers, head of biologic strategy, planning and operations at Elan.

Elan is a biotech with a focus on developing therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Financial details were not disclosed.

The partnership will make use of Boehringer's High Expression Technology (BI HEX) platform, which aims to speed up development times for biological entities, such as antibodies.

"This is a first step in our new strategy engaging our technology platforms at a very early stage in product development," said Simon Sturge, corporate senior vice president of Boehringer's biopharmaceutical division.

Dr Dale Schenk, chief scientific officer, Elan, said the partnership would increase the productivity and potential of the company's development plans for antibodies: "These programmes are broad in scope and are innovative across technology, targets and possible disease application."

10th February 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...